Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector, reports Pink Sheet, Citeline Regulatory insights.citeline.com/pink-sheet/geo…

CPHI Japan 2025 has Ian Haydock presenting global R&D trends from Citeline. Cancer remains at the top focus with Chinese firms’ growing presence.

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears. insights.citeline.com//scrip/focus-o…

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says #Tariffs #Trump #Pharmaceuticals #business insights.citeline.com//scrip/busines…

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years. insights.citeline.com//scrip/focus-o…

The 2025 Scrip Awards Is Open For Entries ow.ly/UeZT10668gF #PharmaScrip

Medicare Price Negotiation: Trump Order Adds Momentum To ‘Pill Penalty’ Fix insights.citeline.com//pink-sheet/ma…

Leqembi Launch Set For Germany & Austria After Winning EU Approval At Last insights.citeline.com//pink-sheet/pr…

Cancer Retains Top Spots In Alliance Deal Volume, Value insights.citeline.com//scrip/busines…

A PMC request sent after the user fee goal date is highly unusual. FDA guidance tells reviewers to provide a list of potential postmarketing commitments & requirements near a target date that “will be no later than one month prior to the PDUFA goal date." insights.citeline.com/pink-sheet/vac…

Great interview by Dexter Yan for Scrip, Citeline Commercial on how Zai is pivoting to innovation #pharma Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets insights.citeline.com//scrip/focus-o…

Quick Listen: Scrip’s Five Must-Know Things ow.ly/9qLZ10689cf #PharmaScrip

Multiple Launches Help Lilly’s Japan Growth ow.ly/Fy7l1068Xwy #PharmaScrip

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear insights.citeline.com//scrip/focus-o…

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint insights.citeline.com//scrip/busines…

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France insights.citeline.com//pink-sheet/ri…

Otsuka’s IgAN Data Top Some Vera Results, But To What End? insights.citeline.com//scrip/busines…

‘Clean Sweep’ Of US CDC Vaccine Committee Puts Kennedy In Driver’s Seat insights.citeline.com//pink-sheet/va…

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home. insights.citeline.com//pink-sheet/ma…

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges, Scrip, Citeline Commercial reports. insights.citeline.com/scrip/digital-…